Rigel Pharmaceuticals Releases Comprehensive Five-Year Findings on REZLIDHIA® for R/R mIDH1 AML Treatment Rigel Pharmaceuticals has published final five-year results demonstrating the efficacy and safety of REZLIDHIA® in patients with R/R mIDH1 AML, offering hope for improved outcomes.

Rigel Pharmaceuticals Releases Comprehensive Five-Year Findings on REZLIDHIA® for R/R mIDH1 AML Treatment #United_States #South_San_Francisco #Rigel_Pharmaceuticals #REZLIDHIA #mIDH1_AML

Rigel Pharmaceuticals to Present Key Data at ASH Annual Meeting 2025 Focused on Innovative Hematologic Therapies Rigel Pharmaceuticals is set to showcase vital data at the 67th ASH Annual Meeting, emphasizing breakthroughs in treating hematologic disorders including AML and MDS.

Rigel Pharmaceuticals to Present Key Data at ASH Annual Meeting 2025 Focused on Innovative Hematologic Therapies #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #mIDH1_AML